Together, this evidence strongly suggests that EPHA2 acts as an oncogene in the ESCC, becoming a promising therapeutic target, which justifies in-depth mechanistic studies in additional in vitro, transgenic, and PDX mouse models. Here, EPHA2 is linked to esophageal squamous cell carcinoma.